Asia Pacific's NSCLC market to show robust growth by 2019

An ageing population and increasing number of NSCLC incident cases, especially in China and India, will be the main drivers behind the anticipated market growth


The NSCLC pipeline seems strong with a total of 290 active molecules in development

The GBI Research has revealed that the non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region - Australia, China, India and Japan - is likely to increase at CAGR of 6.3 percent during 2012-2019 to $2.9 billion by 2019 from $1.8 billion in 2012.

Japan and China had the largest shares of the region's NSCLC market in 2012, with 48.5 percent and 41.5 percent, respectively.

Meanwhile, Australia and India had lower shares of 5.9 percent and 4.1 percent.

"Additionally, the expected launches of premium-priced novel antibodies and immunotherapies in the first and second lines of therapies, targeting both Squamous and Non-Squamous NSCLC patients, will widen the eligible treatment population. This will ultimately maximize the patient share and provide a boost for the market," commented Ms Sravanthi Addapally, senior analyst, GBI Research.

Currently, the NSCLC pipeline is very strong, with a total of 290 active molecules in development, either as monotherapies or in combination with chemotherapy.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email